Pharmacogenetics in Jewish populations.
Drug Metabolism and Drug Interactions
|May 29, 2014
Summary
The Jewish population possesses unique genetic variations influencing drug responses. Research highlights specific pharmacogenetic variants, like those in VKORC1 and CYP2C19, offering insights into personalized medicine for this group.
Area of Science:
- Pharmacogenetics
- Population Genetics
- Genomics
Background:
- The Jewish population exhibits a distinct genetic architecture due to a history of migration, isolation, and population dynamics.
- Previous studies have identified unique Mendelian disease genes and founder mutations within various Jewish groups.
- Limited research exists on pharmacogenetic determinants of drug response variability in the Jewish population.
Purpose of the Study:
- To review and summarize the current pharmacogenetics literature concerning the Jewish population.
- To identify and discuss unique pharmacogenetic variants prevalent in Jewish groups.
- To explore future research directions in Jewish pharmacogenetics.
Main Methods:
- Literature review of existing pharmacogenetics studies in the Jewish population.
- Identification of specific pharmacogenetic variants and their associations with drug response.
- Analysis of genetic data from Ashkenazi Jewish (AJ) and other Jewish groups.
Main Results:
- Several unique pharmacogenetic variants, uncommon in other populations, have been identified in Jewish groups.
- Examples include VKORC1 c.106G>T (p.D36Y) affecting warfarin dosing and CYP2C19*4B with combined functional variants.
- Common multi-ethnic variants in drug metabolism genes (e.g., ABCB1, CYP2C19, CYP2D6) are also present.
Conclusions:
- The Jewish population harbors numerous pharmacogenetic variants that are rare or absent in other ethnicities.
- These unique variants present opportunities for personalized medicine and improved drug efficacy.
- Further research is warranted to fully characterize the pharmacogenetic landscape of the Jewish population.
More Related Videos
05:53Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
9.2K
08:04Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
Published on: June 6, 2025
1.5K
Related Concept Videos
01:27Principles of Pharmacogenetics: Types of Genetic Variants
137
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
137
01:29Pharmacogenetics and Pharmacogenomics: Overview
248
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
248
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
157
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
157
01:27Pharmacogenetics of Drug Metabolism: Overview
191
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
191
01:29Pharmacogenomics: Identification of New Drug Targets
119
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
119
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
337
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
337